Bioreactor strategy in regenerative medicine: an integrated method for engineering parameters, kinetic of cell growth rate and scaffold for 3D-tissue and organ

Introduction Commercialization of regenerative medicine products is a challenge. Most promising technique is 3D tissue engineering that act as a strategy for improving the commercialization challenges such as angiogenesis and density of cells on scaffold on pre-implantation stage. Tissue engineering bioreactors are used to develop 3D cell laden scaffold by providing conditions that mimic their native microenvironment. In-silico investigations can describe the relationship of engineering approaches and biological parameter. Objectives It is possible to match engineering parameters to the biological cell growth conditions by simulation. Mass transport phenomena (such as oxygen transfer, fluid shear stress, and mechanical loading), scaffold structure design (such as porosity, dimension, and structure), and operational parameters integrated in simulation and optimized to achieve to the high efficient pre-implantable 3D cell laden scaffold in in-vitro. Angiogenesis in the 3D scaffold for large defect is the most challenge of commercialized tissue engineering products that can improved in this integrated system. Results and Conclusion These In-vitro integrated systems can be commercialized by an automatic production process modification to achieve safety and reproducible tissue engineered products in future.

Keywords:

Bioreactor , Medicine , Challenge , Commercialization